Eli Lilly's GLP-1 drug adds new indication for combined insulin therapy

2025-07-28 17:13:30

On July 28, reporters learned that Eli Lilly's GLP-1 drug telportin injection (trade name: Mufengda) was recently approved by the China National Drug Administration, with a new indication: used in combination with insulin (with or without oral hypoglycemic drugs) on the basis of diet control and exercise to improve blood sugar control in adult patients with type 2 diabetes (T2DM).

Lilly

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.
                            2025-07-29

                                    Toyota Motor Corp. is expected to decide as early as Wednesday evening whether to resume operations at its Japanese factories.
                            2025-07-30

                                    The world's first active safety AI battery cell goes into mass production
                            2025-07-27

                                    CATL's losses widened in the afternoon, with A shares falling more than 4% to below 280 yuan and H shares falling more than 7%.
                            2025-07-30

                                    BYD: Sales of new energy vehicles in July were 344,296 units. The cumulative sales of new energy vehicles from January to July were 2,490,250 units, a year-on-year increase of 27.35%.
                            2025-08-01